New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategy

11Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

PIN1 is considered as a therapeutic target for a wide variety of tumours. However, most of known inhibitors are devoid of cellular activity despite their good enzyme inhibitory profile. Hence, the lack of effective compounds for the clinic makes the identification of novel PIN1 inhibitors a hot topic in the medicinal chemistry field. In this work, we reported a virtual screening study for the identification of new promising PIN1 inhibitors. A receptor-based procedure was applied to screen different chemical databases of commercial compounds. Based on the whole workflow, two compounds were selected and biologically evaluated. Both ligands, compounds VS1 and VS2, showed a good enzyme inhibitory activity and VS2 also demonstrated a promising antitumoral activity in ovarian cancer cells. These results confirmed the reliability of our in silico protocol and provided a structurally novel ligand as a valuable starting point for the development of new PIN1 inhibitors.

Cite

CITATION STYLE

APA

Poli, G., Di Stefano, M., Estevez, J. A., Minutolo, F., Granchi, C., Giordano, A., … Rizzolio, F. (2022). New PIN1 inhibitors identified through a pharmacophore-driven, hierarchical consensus docking strategy. Journal of Enzyme Inhibition and Medicinal Chemistry, 37(1), 145–150. https://doi.org/10.1080/14756366.2021.1979970

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free